LIVIVO - Search results -

Search results

Result 1 - 10 of total 40

Search options

Article: [ELABORATION AND TREATMENT DECISION IN INCIDENTAL SPLANCHNIC VEIN THROMBOSIS].

Rozano Gorelick, Ayala / Zuckerman, Eli

2019 Volume 158, Issue 3, Page(s) 176–179

Abstract: Introduction: In the present article, a patient with incidental findings in computerized tomography (CT) of cavernous transformation of the splanchnic veins, thrombosis of the splenic and portal veins, esophagus and gastric varicose veins and ... ...

Abstract	Introduction: In the present article, a patient with incidental findings in computerized tomography (CT) of cavernous transformation of the splanchnic veins, thrombosis of the splenic and portal veins, esophagus and gastric varicose veins and splenomegaly is presented. The CT was performed due to mild chronic normocytic anemia known for two years and the elevated level of LDH (Lactic dehydrogenase). Although usually such incidental findings without cirrhosis do not necessitate anticoagulation therapy according to the literature, in cases of myeloproliferative diseases, anticoagulation is required in order to prevent thrombus propagation. The Calreticulin (CALR) mutation is associated with more bleeding tendency and less thrombotic manifestations while the Janus kinase 2 V617F (JAK-2) mutation increases the risk of thrombosis. In the present article, we present the case report and review the relevant literature.
MeSH term(s)	Humans ; Janus Kinase 2 ; Mutation ; Myeloproliferative Disorders ; Portal Vein ; Splanchnic Circulation ; Thrombosis/diagnosis ; Thrombosis/therapy ; Venous Thrombosis
Chemical Substances	Janus Kinase 2 (EC 2.7.10.2)
Language	Hebrew
Publishing date	2019-03-26
Publishing country	Israel
Document type	Journal Article
ZDB-ID	953872-0
ISSN	0017-7768
ISSN	0017-7768
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 291: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Vital hepatitis reactivation with anti-tumor necrosis factor-alpha: what do we know?

Zuckerman, Eli

The Israel Medical Association journal : IMAJ

2013 Volume 15, Issue 6, Page(s) 298–300

MeSH term(s)	Crohn Disease/drug therapy ; Hepatitis B, Chronic/diagnosis ; Hepatitis C, Chronic/diagnosis ; Humans ; Rheumatic Diseases/drug therapy ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Virus Activation/drug effects
Chemical Substances	Tumor Necrosis Factor-alpha
Language	English
Publishing date	2013-06
Publishing country	Israel
Document type	Comment ; Editorial
ZDB-ID	2008291-5
ISSN	1565-1088 ; 0021-2180
ISSN	1565-1088 ; 0021-2180
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5470: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Treatment of hepatitis C virus--2012: a real breakthrough].

Zuckerman, Eli

Harefuah

2012 Volume 151, Issue 12, Page(s) 699–704, 719

Abstract: For almost a decade the standard of care (SOC) therapy in patients with chronic hepatitis C virus (HCV) infection has consisted of a 24-48 week course of pegylated interferon-alpha in combination with ribavirin. This therapy is associated with ... ...

Abstract	For almost a decade the standard of care (SOC) therapy in patients with chronic hepatitis C virus (HCV) infection has consisted of a 24-48 week course of pegylated interferon-alpha in combination with ribavirin. This therapy is associated with significant adverse effects and leads to sustained virological response (SVR) in only 50% of patients with genotype 1. The development of compounds with direct antiviral activity (DAAs) against HCV genotype 1 during the past 10 years has led to the most significant breakthrough since the virus was first identified in 1989, Leading to a real revolution in the treatment of chronic HCV infection. The combination of the new DAAs with the SOC therapy has led to a significant improvement in achieving SVR in treatment-naïve (30%), as well as in treatment-experienced patients with genotype 1 (24-64%, depending on the response to previous antiviral treatment). In addition, treatment with DAAs enables shortening therapy in certain subgroups of patients, without compromising the SVR rate. However, the new treatment is challenging as it is associated with more severe adverse effects, complicated treatment regimens, need for frequent monitoring, drug-drug interaction, tolerance problems and development of selected resistant strains. This review updates the current information regarding DAAs, the new challenges that we will have to face and the therapeutic horizon in the near future.
MeSH term(s)	Antiviral Agents/adverse effects ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Drug Design ; Drug Interactions ; Drug Monitoring ; Drug Resistance, Viral ; Genotype ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology ; Humans
Chemical Substances	Antiviral Agents
Language	Hebrew
Publishing date	2012-12
Publishing country	Israel
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	953872-0
ISSN	0017-7768
ISSN	0017-7768
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 291: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prevalence of elevated liver enzymes and comorbidities in children and adolescents with overweight and obesity.

Hartman, Corina / Rennert, Hedy S / Rennert, Gad / Elenberg, Yigal / Zuckerman, Eli

Acta paediatrica (Oslo, Norway : 1992)

2020 Volume 110, Issue 3, Page(s) 985–992

Abstract: Aim: We investigated the prevalence of elevated liver aminotransferases (ALT) and additional comorbidities in a large cohort of Israeli children and adolescents with overweight and obesity.: Methods: This study included data from medical records of 2- ...

Abstract	Aim: We investigated the prevalence of elevated liver aminotransferases (ALT) and additional comorbidities in a large cohort of Israeli children and adolescents with overweight and obesity. Methods: This study included data from medical records of 2- to 18-year-old children and adolescents, with body mass index (BMI) in the overweight or obesity range (WHO definitions), for whom ALT testing was performed. Results: Overweight was present in 50 418 (10.7%) and obesity in 70 515 (15.0%). Elevated ALT, above 30 IU/L (0.51 μkat/L), was reported in 2245 (7.2%) of children with overweight and 5475 (16.8%) of children with obesity (P < .0001). Compared to children with overweight and obesity and ALT within normal range, children with elevated ALT were older (11.9 ± 4.2 vs 10.9 ± 4.2, P < .001), mostly male (68.0% vs 49.4%, P < .001) and had higher BMI (27.3 ± 6.1vs 24.0 ± 4.8, P < .001). They also had a more unfavourable cardiometabolic profile with significantly higher either systolic or diastolic blood pressure, total cholesterol and triglycerides, and had more than three criteria defining metabolic syndrome. Conclusion: In this large cohort, abnormally elevated ALT was present in a high number of individuals with overweight or obesity. The children and adolescents with abnormal ALT had higher BMI, were older, male and had more cardiometabolic risk factors.
MeSH term(s)	Adolescent ; Alanine Transaminase ; Body Mass Index ; Child ; Child, Preschool ; Female ; Humans ; Liver ; Male ; Obesity/epidemiology ; Overweight/epidemiology ; Prevalence ; Risk Factors
Chemical Substances	Alanine Transaminase (EC 2.6.1.2)
Language	English
Publishing date	2020-07-28
Publishing country	Norway
Document type	Journal Article
ZDB-ID	203487-6
ISSN	1651-2227 ; 0365-1436 ; 0803-5253
ISSN (online)	1651-2227
ISSN	0365-1436 ; 0803-5253
DOI	10.1111/apa.15469
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Um IV Zs.95: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Hepatitis C infection and B-cell non-Hodgkin's lymphoma.

Zuckerman, Eli

Clinical lymphoma

2003 Volume 3, Issue 3, Page(s) 161–162

MeSH term(s)	Hepatitis C/complications ; Hepatitis C/epidemiology ; Hepatitis C/therapy ; Humans ; Liver/pathology ; Liver/virology ; Lymphoma, B-Cell/complications ; Lymphoma, B-Cell/epidemiology ; Lymphoma, B-Cell/therapy ; Treatment Outcome
Language	English
Publishing date	2003-01-10
Publishing country	United States
Document type	Journal Article
ZDB-ID	2145066-3
ISSN	1526-9655
ISSN	1526-9655
DOI	10.1016/s1526-9655(11)70261-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5903: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Expansion of CD5+ B-cell overexpressing CD81 in HCV infection: towards better understanding the link between HCV infection, B-cell activation and lymphoproliferation.

Zuckerman, Eli

Journal of hepatology

2003 Volume 38, Issue 5, Page(s) 674–676

MeSH term(s)	Antigens, CD/metabolism ; B-Lymphocytes/cytology ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; CD5 Antigens/metabolism ; Cell Division/immunology ; Hepatitis C, Chronic/immunology ; Humans ; Lymphocyte Activation ; Membrane Proteins/metabolism ; Tetraspanin 28
Chemical Substances	Antigens, CD ; CD5 Antigens ; CD81 protein, human ; Membrane Proteins ; Tetraspanin 28
Language	English
Publishing date	2003-04-18
Publishing country	Netherlands
Document type	Editorial ; Review ; Comment
ZDB-ID	605953-3
ISSN	1600-0641 ; 0168-8278
ISSN (online)	1600-0641
ISSN	0168-8278
DOI	10.1016/s0168-8278(03)00122-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2027: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Delayed Bleeding after Percutaneous Liver Biopsy.

Dotan, Yaniv / Carlebach, Matthias / Zuckerman, Eli / Maruf, Musa / Schiff, Elad

European journal of case reports in internal medicine

2016 Volume 3, Issue 2, Page(s) 359

Abstract: Percutaneous liver biopsy (PLB) is a common procedure in patients with liver disease. Bleeding after PLB is rare, with an incidence of 0.35%. Most bleeding complications present within 24 h after biopsy. A 56-year-old woman was admitted to our hospital ... ...

Abstract	Percutaneous liver biopsy (PLB) is a common procedure in patients with liver disease. Bleeding after PLB is rare, with an incidence of 0.35%. Most bleeding complications present within 24 h after biopsy. A 56-year-old woman was admitted to our hospital due to severe and sudden right upper quadrant (RUQ) abdominal pain 10 days after ultrasound (US)-guided PLB. CT study revealed both intrahepatic and intraperitoneal bleeding, and Hb levels decreased by 3.2 g/dl within a few hours. Such a prolonged delay in PLB-related bleeding has not been previously described in the medical literature. Learning points: Bleeding after liver biopsy is very rare, with an incidence of 0.35%.Approximately 95% of bleeding complications occur within 24 h.Physicians should be aware of rare delayed presentation in the days following liver biopsy.
Language	English
Publishing date	2016-01-18
Publishing country	Italy
Document type	Journal Article
ISSN	2284-2594
ISSN (online)	2284-2594
DOI	10.12890/2016_000359
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Evaluation and treatment of esophageal varices in the cirrhotic patient.

Ashkenazi, Eyal / Kovalev, Yulia / Zuckerman, Eli

The Israel Medical Association journal : IMAJ

2013 Volume 15, Issue 2, Page(s) 109–115

Abstract: Portal hypertension is the leading cause of morbidity and mortality in liver cirrhosis. Complications of portal hypertension in cirrhotic patients include esophageal and gastric varices, portal hypertensive gastropathy, ascites, hepatorenal syndrome, ... ...

Abstract	Portal hypertension is the leading cause of morbidity and mortality in liver cirrhosis. Complications of portal hypertension in cirrhotic patients include esophageal and gastric varices, portal hypertensive gastropathy, ascites, hepatorenal syndrome, hepatopulmonary syndrome and portopulmonary hypertension. The hepatic venous pressure gradient should be at least 10 mmHg for esophageal varices to appear, and more than 12 mmHg for acute esophageal variceal bleeding. This article reviews the pathophysiology responsible for portal hypertension and its complications, and the treatments used for esophageal varices in the setting of primary and secondary prophylaxis and during active bleeding.
MeSH term(s)	Esophageal and Gastric Varices/diagnosis ; Esophageal and Gastric Varices/etiology ; Esophageal and Gastric Varices/physiopathology ; Esophageal and Gastric Varices/prevention & control ; Humans ; Hypertension, Portal/complications ; Hypertension, Portal/diagnosis ; Hypertension, Portal/physiopathology ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/physiopathology ; Primary Prevention ; Secondary Prevention
Language	English
Publishing date	2013-02
Publishing country	Israel
Document type	Journal Article ; Review
ZDB-ID	2008291-5
ISSN	1565-1088 ; 0021-2180
ISSN	1565-1088 ; 0021-2180
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5470: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Familial Mediterranean fever: an association with non-alcoholic fatty liver disease.

Rimar, Doron / Rosner, Itzhak / Rozenbaum, Michael / Zuckerman, Eli

Clinical rheumatology

2011 Volume 30, Issue 7, Page(s) 987–991

Abstract: The purpose of this study is to characterize the chronic liver disease (CLD) that may be associated with familial Mediterranean fever (FMF). Twenty-seven patients (mean age, 48 ± 18 years; F/M, 16:11) with FMF who were referred for assessment of CLD were ...

Abstract	The purpose of this study is to characterize the chronic liver disease (CLD) that may be associated with familial Mediterranean fever (FMF). Twenty-seven patients (mean age, 48 ± 18 years; F/M, 16:11) with FMF who were referred for assessment of CLD were studied. Data regarding FMF and CLD were obtained from patient medical files. Liver biopsy was performed in 21 of 27 patients and deferred in six (cirrhotic coagulopathy in five and one who improved after colchicine dose reduction). Patients with FMF and non-alcoholic fatty liver disease (NAFLD) were compared to matched controls from a cohort of 150 patients with NAFLD per liver biopsy but without FMF. The mean Tel Hashomer severity score was 1.7 ± 0.9. The mean daily dose of colchicine was 1.4 ± 0.4 mg over a mean duration of 21 years ± 10. Seven of ten patients who underwent mutation analysis for FMF were homozygous for M694V. In 15 patients, there was evidence of NAFLD: five with "simple" steatosis, three with non-alcoholic steatohepatitis (NASH), and seven with NASH-cirrhosis. An additional five patients had "cryptogenic" cirrhosis, which in most patients represents the end result of unrecognized NASH, and one had normal liver tissue. Comparing FMF patients with NAFLD to matched controls with NAFLD did not reveal excess of metabolic syndrome in FMF patients. Of our FMF patients, 74% had evidence of NAFLD, 75% of which with severe manifestation. The extremely high proportion of NAFLD in our cohort of FMF patients without overt metabolic syndrome may indicate an unappreciated novel association between FMF and NAFLD.
MeSH term(s)	Age of Onset ; Biopsy ; Cohort Studies ; Colchicine/therapeutic use ; Comorbidity ; Familial Mediterranean Fever/diagnosis ; Familial Mediterranean Fever/drug therapy ; Familial Mediterranean Fever/epidemiology ; Fatty Liver/diagnosis ; Fatty Liver/epidemiology ; Female ; Humans ; Liver/pathology ; Liver Function Tests ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease ; Retrospective Studies ; Severity of Illness Index ; Young Adult
Chemical Substances	Colchicine (SML2Y3J35T)
Language	English
Publishing date	2011-03-02
Publishing country	Germany
Document type	Journal Article
ZDB-ID	604755-5
ISSN	1434-9949 ; 0770-3198
ISSN (online)	1434-9949
ISSN	0770-3198
DOI	10.1007/s10067-011-1718-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1740: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.

Harrison, Stephen A / Manghi, Federico Perez / Smith, William B / Alpenidze, Diana / Aizenberg, Diego / Klarenbeek, Naomi / Chen, Chi-Yi / Zuckerman, Eli / Ravussin, Eric / Charatcharoenwitthaya, Phunchai / Cheng, Pin-Nan / Katchman, Helena / Klein, Samuel / Ben-Ari, Ziv / Mendonza, Anisha E / Zhang, Yiming / Martic, Miljen / Ma, Shenglin / Kao, Sheena /

Tanner, Sandra / Pachori, Alok / Badman, Michael K / He, YanLing / Ukomadu, Chinweike / Sicard, Eric

Nature medicine

2022 Volume 28, Issue 7, Page(s) 1432–1438

Abstract: Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis that inhibition of both the sodium-glucose ... ...

Abstract	Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis that inhibition of both the sodium-glucose cotransporters 1 and 2 with licogliflozin would lead to improvement in NASH. A total of 107 patients with phenotypic or histologic NASH were randomized (1:2:2) to receive oral administration of either placebo (n = 21), licogliflozin 30 mg (n = 43) or 150 mg (n = 43) once daily for 12 weeks. Licogliflozin 150 mg showed a significant 32% (80% confidence interval (CI): 21-43%; P = 0.002) placebo-adjusted reduction in serum alanine aminotransferase after 12 weeks of treatment, the primary endpoint of the study. However, the 30 mg dose of licogliflozin did not meet the primary endpoint (placebo-adjusted reduction 21% (80% CI: 7-32%; P = 0.061)). Diarrhea occurred in 77% (33 of 43), 49% (21 of 43) and 43% (9 of 21) of patients treated with licogliflozin 150 mg, 30 mg and placebo, respectively, which was mostly mild in severity. No other major safety concerns were identified. Treatment with 150 mg licogliflozin led to reductions in serum alanine aminotransferase in patients with NASH. Studies of longer duration and in combination with drugs that have different mechanisms of action are needed to validate these findings and to define a role of licogliflozin as a therapeutic option for NASH. ClinicalTrials.gov identifier: NCT03205150.
MeSH term(s)	Alanine Transaminase ; Anhydrides/pharmacology ; Anhydrides/therapeutic use ; Double-Blind Method ; Humans ; Non-alcoholic Fatty Liver Disease/drug therapy ; Non-alcoholic Fatty Liver Disease/pathology ; Sorbitol/analogs & derivatives ; Sorbitol/pharmacology ; Sorbitol/therapeutic use ; Treatment Outcome
Chemical Substances	Anhydrides ; Sorbitol (506T60A25R) ; licogliflozin (57J06X6EI0) ; Alanine Transaminase (EC 2.6.1.2)
Language	English
Publishing date	2022-06-20
Publishing country	United States
Document type	Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-022-01861-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito